BioStem Technologies (BSEM) director details options, RSUs and stock stake
Rhea-AI Filing Summary
BioStem Technologies, Inc. director Kenneth Howard Warrington Jr. reported his equity holdings. He holds a stock option for 7,462 shares of common stock at an exercise price of $1.80 per share, expiring on March 29, 2032, which is fully vested and exercisable. He also holds restricted stock units (RSUs) covering 8,467 shares that vest in equal quarterly installments over three years from the grant date of September 15, 2024, and additional RSUs covering 5,094 shares that vest in equal quarterly installments over the year following the grant date of August 27, 2025. Each RSU represents a contingent right to receive one share of common stock. In addition, he directly owns 27,140 shares of common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
4 transactions reported
Mixed
4 txns
Insider
WARRINGTON KENNETH HOWARD JR
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) F1 | -- | -- | -- |
| holding | Restricted Stock Units F3, F2 | -- | -- | -- |
| holding | Restricted Stock Units F3, F4 | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 7,462 shares (Direct);
Restricted Stock Units — 13,561 shares (Direct);
Common Stock — 27,140 shares (Direct)
Footnotes (4)
- F1. These options are fully vested and exercisable.
- F2. These restricted stock units vest in equal quarterly installments over 3 years from the grant date (September 15, 2024).
- F3. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
- F4. These restricted stock units vest in equal quarterly installments over the year following the grant date (August 27, 2025).
Key Figures
Common stock directly owned: 27,140 shares
Stock option underlying shares: 7,462 shares
Stock option exercise price: $1.80 per share
+3 more
6 metrics
Common stock directly owned
27,140 shares
Direct common stock holdings reported by Kenneth Howard Warrington Jr.
Stock option underlying shares
7,462 shares
Fully vested stock option to buy common stock
Stock option exercise price
$1.80 per share
Exercise price for 7,462-share stock option expiring March 29, 2032
Stock option expiration
March 29, 2032
Expiration date of fully vested stock option
RSUs grant 1 underlying shares
8,467 shares
RSUs vesting quarterly over three years from September 15, 2024
RSUs grant 2 underlying shares
5,094 shares
RSUs vesting quarterly over the year following August 27, 2025
Key Terms
Restricted Stock Units, Stock Option (Right to Buy), contingent right, vest in equal quarterly installments
4 terms
Restricted Stock Units financial
"These restricted stock units vest in equal quarterly installments over 3 years"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) for common stock at an exercise price of $1.80"
contingent right financial
"Each restricted stock unit represents a contingent right to receive one share"
vest in equal quarterly installments financial
"These restricted stock units vest in equal quarterly installments over 3 years"
FAQ
What did BioStem Technologies (BSEM) disclose about Kenneth Warrington Jr.'s stock options?
Kenneth Howard Warrington Jr. holds a fully vested stock option for 7,462 shares of BioStem Technologies common stock at an exercise price of $1.80 per share, expiring on March 29, 2032. These options are currently exercisable according to the disclosure.
How many RSUs does Kenneth Warrington Jr. hold in BioStem Technologies (BSEM)?
He holds two restricted stock unit awards totaling 13,561 underlying shares: 8,467 RSUs vesting quarterly over three years from September 15, 2024, and 5,094 RSUs vesting quarterly over the year following August 27, 2025. Each RSU equals one common share.
What common stock holdings does Kenneth Warrington Jr. report in BioStem Technologies (BSEM)?
Kenneth Howard Warrington Jr. reports direct ownership of 27,140 shares of BioStem Technologies common stock. This is in addition to his stock options and restricted stock units, which, if exercised or vested, would increase his effective equity exposure.
Do Kenneth Warrington Jr.’s options in BioStem Technologies (BSEM) have a specific expiration date?
Yes. His reported stock option for 7,462 underlying shares of BioStem Technologies common stock carries an exercise price of $1.80 and an expiration date of March 29, 2032. The filing states these options are fully vested and exercisable.
How do the RSUs for BioStem Technologies (BSEM) vest for Kenneth Warrington Jr.?
One RSU grant of 8,467 shares vests in equal quarterly installments over three years from September 15, 2024. Another grant of 5,094 shares vests in equal quarterly installments over the year following August 27, 2025, each RSU converting into one common share upon vesting.
AI-generated analysis. How Rhea-AI works. Not financial advice.
